Mechanistic and clinical insights at the scleroderma-cancer interface
Emerging data suggest tantalizing links between cancer and systemic inflammatory rheumatic syndromes. In scleroderma, patients may have an increased risk of cancer, secondary to chronic inflammation and damage from the disease, malignant transformation promoted by immunosuppressive therapies, a shared susceptibility to both cancer and autoimmunity, or a common inciting exposure. However, it is increasingly recognized that a subset of patients develop cancer around the time that scleroderma clinically manifests, raising the question of cancer-induced autoimmunity. In this review, we discuss data suggesting a mechanistic link between cancer and the development of scleroderma, and the clinical implications of these findings.
J scleroderma relat disord
2017; 2(3): 153 - 159
Article Type: REVIEW
Ami A. Shah, Livia Casciola-Rosen
• Accepted on 30/06/2017
• Available online on 02/08/2017
• Published in print on 05/10/2017
Financial support: This work was funded in part by the National Institutes of Health (K23 AR061439), the Scleroderma Research Foundation, the Donald B. and Dorothy L. Stabler Foundation, and the Jerome L. Greene Foundation.
Conflict of interest: None of the authors has financial interest related to this study to disclose.
You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.